Targeting the mTOR Pathway for the Prevention of ER-Negative Breast Cancer.
Abhijit MazumdarWilliam M TahaneyJamal L HillYun ZhangRamachandran SumankalaiJitesh KawediaJing QianAlejandro ContrerasMichelle I SavageLana A VornikShizuko SeiAltaf MohammedPowel H BrownPublished in: Cancer prevention research (Philadelphia, Pa.) (2022)
Our results show that everolimus delays mammary tumor formation in multiple mouse models, suggesting that mTOR inhibitors will be useful for the prevention of ER-negative and triple-negative breast cancer in humans. See related Spotlight, p. 787.